BrainStorm announces results from NurOwn Phase 2 trial
BrainStorm announced that their scientific abstract received the clinical abstract award at this year's Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, conference. To relate CSF miRNA changes to CSF biomarkers of apoptosis and innate immune activation in pre- and 2-weeks post-intrathecal transplantation of MSC-NTF cells in a NurOwn Phase 2 trial. The biomarker data demonstrated increases in miRNA 132 and miRNA 146a and statistically significant decreases in MCP-1, SDF-1, CHIT-1 and Caspase-3 levels in CSF following a single MSC-NTF cell transplantation in the NurOwn Phase 2 trial. The data presented suggests that miRNA secreted by MSC-NTF cells may contribute to CSF biomarker evidence of neuroprotection and immunomodulation. Additional miRNA evaluation and biomarker correlations will be examined in the ongoing NurOwn Phase 3 pivotal trial in ALS.